Skip to content

Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis

Effect of Progressive Muscle Relaxation as a Nursing Intervention on Sleep Quality, Depression and Stress in People With Multiple Sclerosis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02673827
Enrollment
40
Registered
2016-02-04
Start date
2014-04-30
Completion date
2015-07-31
Last updated
2016-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Multiple Sclerosis, Sleep, Stress Psychological

Brief summary

Objective: Evaluate the effects of Progressive Muscle Relaxation on sleep quality and on stress and depression levels of individuals with multiple sclerosis.

Detailed description

Introduction: Multiple sclerosis is a chronic, autoimmune disease, characterized by demyelination and neurodegeneration of the central nervous system. The progressive course of this disease may cause individuals to develop extreme dependency and create serious difficulties both to the individuals themselves and family members and caregivers, since the disease brings a number of physical, emotional, psychological and social symptoms. Therefore, it is essential to offer healthcare practices that go beyond the usually fragmenting, dehumanized care services that focus on the disease bodily processes. Objective: Evaluate the effects of Progressive Muscle Relaxation on sleep quality and on stress and depression levels of individuals with multiple sclerosis. Methodology: This is randomized clinical test. The sample was made up of 40 individuals with multiple sclerosis (20 in control group and 20 in the experimental group) in outpatient follow-up. The progressive muscle relaxation technique was employed. In order to collect the data, we adopted the interview with form filling technique, using the Pittsburgh Sleep Quality Index, Perceived Stress Scale and Beck Depression Inventory. Blood pressure, heart rate and respiratory rate of experimental group were measured before and after the progressive muscle relaxation intervention. In order to treat statistical data, we used Statistical Package for Social Sciences, version 19.0.

Interventions

OTHERProgressive muscle relaxation

Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.

Sponsors

Federal University of Espirito Santo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* To be diagnosed with Multiple Sclerosis for at least 6 months * To be diagnosed with relapsing-remitting multiple sclerosis * To have Expanded Disability Status Scale score \< 5.0 * To not have had any attacks during the 3-month period preceding enrollment in the study * To have audio at home * To be residing in the Metropolitan region of Vitória-Espirito Santo-Brazil. * To be 18-65 years of age * Treatment with an immunomodulator

Exclusion criteria

* Being hospitalized at the time of data collection or outbreak at the time of data collection * Have physical and / or mental changes that prevent the collection of data, such as motor or cognitive deficits * Experiencing relapse and/or corticosteroid use within the last month, diagnosed with progressive MS (primary or secondary) * Use of psychotropic drugs (antidepressants, benzodiazepines, antipsychotic and cannabis, or other stimulants), * Practice of other relaxation techniques (yoga, pilates, meditation, psychotherapy)

Design outcomes

Primary

MeasureTime frameDescription
Stress Level2 monthsInstrument: Perceived Stress Scale.

Secondary

MeasureTime frameDescription
Level of depression2 monthsInstrument : Beck Depression Inventory.
sleep quality2 monthsInstrument: Pittsburgh Sleep Quality Index.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026